Sana Biotechnology (SANA) Price & Analysis

Compare

653 Followers

SANA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.26 - $7.30

Previous CloseN/A

Volume118.31M

Average Volume (3M)5.18M

Market Cap

$960.87M

Enterprise Value$381.55M

Total Cash (Recent Filing)$104.70M

Total Debt (Recent Filing)$91.31M

Price to Earnings (P/E)―

Beta1.36

Next Earnings

Nov 05, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding225,555,370

10 Day Avg. Volume4,476,173

30 Day Avg. Volume5,180,361

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.40

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-97.96

Enterprise Value/Ebitda-1.97

Forecast

1Y Price Target

$9.80

Price Target Upside131.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Innovative ApproachSana's innovative approach and strategic focus position it as a company to watch in the evolving cell therapy landscape.

Product DevelopmentThe positive early data for UP421 provides proof-of-concept for this approach, and the development of SC451 holds promise for a sustainable solution.

Regulatory ProgressThe favorable engagement with FDA is a key positive that potentially moves SC451 closer to the clinic.

Bears Say

Regulatory RequirementsSana has guided to a near-term regulatory interaction to ensure FDA alignment that the master cell bank meets requirements for quality and stability, which will be important for better defining timelines to IND filing.

Sana Biotechnology News

Why Is Sana Biotechnology Stock Down 25% Today?

Sana Biotechnology stock fell hard on Thursday after the company announced the price of shares in a public offering. ...

7h ago

SANA

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories

Investors looking for all of the hottest stock market stories for Thursday are in the right place! ...

15h ago

AMD

Apple invests extra $100B in U.S., Trump wants Intel CEO to resign: Morning Buzz

The major averages were mixed near noon, with the Nasdaq the lone gainer as traders digest another wave...

15h ago

CAT

Sana Biotechnology 20.9M share Spot Secondary priced at $3.35

The deal range was $3.35-$3.70. Morgan Stanley, Goldman Sachs, BofA and TD Cowen acted as joint book running...

21h ago

SANA

Sana Biotechnology announces $75M common stock offering

Sana Biotechnology (SANA) announced that it has commenced an underwritten public offering of $75M of shares of its...

1d ago

SANA

Sana Biotechnology announces publication on clinical data from transplantation

Sana Biotechnology (SANA) announced that the New England Journal of Medicine has published a journal article titled “Survival...

4d ago

SANA

Sana Biotechnology Announces Public Offering Pricing

Sana Biotechnology ( ($SANA) ) has provided an announcement. On August 6, 2025, Sana Biotechnology, Inc. announced the...

9h ago

SANA

Sana Biotechnology Reports Non-Cash Impairment Losses

Sana Biotechnology ( ($SANA) ) has issued an update. In a recent update, Sana Biotechnology reported preliminary financial...

1d ago

SANA

Promising Developments and FDA Engagement Bolster Buy Rating for Sana Biotechnology

Analyst Samantha Semenkow of Citi reiterated a Buy rating on Sana Biotechnology, retaining the price target of $15.00....

3d ago

SANA

Positive Outlook on Sana Biotechnology Driven by Promising T1D Program and Allogeneic CAR-T Advancements

Citi analyst Samantha Semenkow has maintained their bullish stance on SANA stock, giving a Buy rating on July...

1M ago

SANA

Sana Biotechnology assumed with an Overweight at Morgan Stanley

Morgan Stanley analyst Maxwell Skor assumed coverage of Sana Biotechnology (SANA) with an Overweight rating and $12 price...

1M ago

SANA

Sana Biotechnology Announces Positive Diabetes Study Results

Sana Biotechnology ( ($SANA) ) has provided an announcement. On June 23, 2025, Sana Biotechnology announced positive six-month...

2M ago

SANA

Sana reports six-month follow-up results from islet cell transplantation study

Sana Biotechnology (SANA) announced six-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet...

2M ago

SANA

Sana Biotechnology Elects Directors at Annual Meeting

Sana Biotechnology ( ($SANA) ) has provided an announcement. On June 5, 2025, Sana Biotechnology held its annual...

2M ago

SANA

SANA FAQ

What was Sana Biotechnology, Inc.’s price range in the past 12 months?

Sana Biotechnology, Inc. lowest stock price was $1.26 and its highest was $7.30 in the past 12 months.

What is Sana Biotechnology, Inc.’s market cap?

Sana Biotechnology, Inc.’s market cap is $960.87M.

When is Sana Biotechnology, Inc.’s upcoming earnings report date?

Sana Biotechnology, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.

How were Sana Biotechnology, Inc.’s earnings last quarter?

Currently, no data Available

Is Sana Biotechnology, Inc. overvalued?

According to Wall Street analysts Sana Biotechnology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sana Biotechnology, Inc. pay dividends?

Sana Biotechnology, Inc. does not currently pay dividends.

What is Sana Biotechnology, Inc.’s EPS estimate?

Sana Biotechnology, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sana Biotechnology, Inc. have?

Sana Biotechnology, Inc. has 225,555,370 shares outstanding.

What happened to Sana Biotechnology, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sana Biotechnology, Inc.?

Currently, no hedge funds are holding shares in SANA

Sana Biotechnology Stock Smart Score

Outperform

Fundamentals

Return on Equity

-71.44%

Trailing 12-Months

Asset Growth

-34.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology (SANA) Earnings & Revenues

Historic Earnings Reports

SANA Stock 12 Month Forecast

Average Price Target

$9.80

▲(131.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.91,4.763076923076923,5.616153846153846,6.469230769230769,7.322307692307692,8.175384615384615,9.028461538461539,9.881538461538462,10.734615384615385,11.587692307692308,12.44076923076923,13.293846153846154,14.146923076923077,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.91,4.363076923076923,4.8161538461538465,5.269230769230769,5.722307692307693,6.1753846153846155,6.628461538461538,7.081538461538462,7.534615384615385,7.987692307692308,8.44076923076923,8.893846153846155,9.346923076923076,{"y":9.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.91,3.993846153846154,4.077692307692308,4.161538461538462,4.245384615384616,4.32923076923077,4.413076923076924,4.496923076923077,4.5807692307692305,4.664615384615384,4.748461538461538,4.832307692307692,4.916153846153846,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.63,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >